CAM
VRTX icon

Chesapeake Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Chesapeake Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Sell
53
-10
-16% -$4.43K 0.02% 184
2026
Q1 		$28.1K Hold
63
– – 0.02% 180
2025
Q4 		$28.6K Hold
63
– – 0.02% 186
2025
Q3 		$24.7K Buy
63
+33
+110% +$13.8K 0.02% 176
2025
Q2 		$13.4K Buy
30
+28
+1,400% +$12.9K 0.01% 198
2025
Q1 		$969 Sell
2
-1
-33% -$466 ﹤0.01% 363
2024
Q4 		$1.21K Buy
3
+1
+50% +$464 ﹤0.01% 315
2024
Q3 		$930 Buy
+2
New +$961 ﹤0.01% 311

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Chesapeake Asset Management's VRTX Position: Q2 2026 in Review

Chesapeake Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, selling an estimated $4.43K and leaving 53 shares worth $26.3K. The position accounts for 0.02% of the portfolio, ranked #184.

Chesapeake Asset Management first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $28.6K in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Chesapeake Asset Management held 53 shares of Vertex Pharmaceuticals worth $26.3K as of Q2 2026.
  • Chesapeake Asset Management sold 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.43K.
  • Vertex Pharmaceuticals made up 0.02% of Chesapeake Asset Management's portfolio in Q2 2026, its #184 holding.
  • Chesapeake Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Chesapeake Asset Management's Vertex Pharmaceuticals position peaked at $28.6K in Q4 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chesapeake Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.